{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:26:51Z","timestamp":1791588411119,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.thromres.2020.12.030","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T17:39:20Z","timestamp":1610041160000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Translating the success of prophylaxis in haemophilia to von Willebrand disease"],"prefix":"10.1016","volume":"199","author":[{"given":"Wolfgang","family":"Miesbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Berntorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2020.12.030_bb0005","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0010","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/hae.13589","article-title":"Value of prophylaxis vs on-demand treatment: application of a value framework in hemophilia","volume":"24","author":"Nugent","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0015","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","article-title":"The benefits of prophylaxis in patients with hemophilia B","volume":"11","author":"Castaman","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.thromres.2020.12.030_bb0020","first-page":"165","article-title":"Prophylaxis in haemophilia should be life-long","volume":"10","author":"Makris","year":"2012","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2020.12.030_bb0025","first-page":"364","article-title":"Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?","volume":"11","author":"den Uijl","year":"2013","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2020.12.030_bb0030","author":"Klamroth","year":"2019"},{"key":"10.1016\/j.thromres.2020.12.030_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0045","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.12.030_bb0050","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V99.7.2337","article-title":"The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia","volume":"99","author":"Fischer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.12.030_bb0055","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/MBC.0000000000000392","article-title":"Yes or no for secondary prophylaxis in afibrinogenemia?","volume":"26","author":"Simurda","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2020.12.030_bb0060","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2017.168617","article-title":"Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study","volume":"102","author":"van Galen","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2020.12.030_bb0065","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/hae.12670","article-title":"Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study","volume":"21","author":"van Galen","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0070","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1055\/s-0038-1670704","article-title":"Long-term outcome after joint bleeds in Von Willebrand disease compared to haemophilia A: a post hoc analysis","volume":"118","author":"van Galen","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2020.12.030_bb0075","first-page":"s3","article-title":"Role of von Willebrand factor in the haemostasis","volume":"9","author":"Peyvandi","year":"2011","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2020.12.030_bb0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0085","author":"World Federation of Hemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143913","article-title":"Identification and characterization of novel variations in platelet G-protein coupled receptor (GPCR) genes in patients historically diagnosed with type 1 von Willebrand disease","volume":"10","author":"Stockley","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2020.12.030_bb0095","author":"World Federation of Hemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0100","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40265-017-0793-2","article-title":"Current and emerging options for the management of inherited von Willebrand disease","volume":"77","author":"Heijdra","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.thromres.2020.12.030_bb0105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2020.12.030_bb0110","author":"National Haemophilia Foundation"},{"key":"10.1016\/j.thromres.2020.12.030_bb0115","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2013-06-498303","article-title":"von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy","volume":"122","author":"Lillicrap","year":"2013","journal-title":"Blood"},{"issue":"Suppl. 4","key":"10.1016\/j.thromres.2020.12.030_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2012.02822.x","article-title":"WFH: closing the global gap--achieving optimal care","volume":"18","author":"Skinner","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0125","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1111\/hae.13215","article-title":"Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement","volume":"23","author":"Iorio","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0130","first-page":"371","article-title":"Current challenges in the diagnosis and management of patients with inherited von Willebrand\u2019s disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis","volume":"16","author":"Schinco","year":"2018","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2020.12.030_bb0135","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1055\/s-0037-1599145","article-title":"Angiodysplasia in von Willebrand disease: understanding the clinical and basic science","volume":"43","author":"Selvam","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0140","author":"The American Society of Hematology"},{"key":"10.1016\/j.thromres.2020.12.030_bb0145","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.thromres.2020.12.030_bb0150","author":"National Heart Lung and Blood Institute"},{"key":"10.1016\/j.thromres.2020.12.030_bb0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/rth2.12256","article-title":"Bleeding assessment tools to predict von Willebrand disease: utility of individual bleeding symptoms","volume":"4","author":"Spradbrow","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0160","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0165","series-title":"The Diagnosis, Evaluation, and Management of von Willebrand Disease","author":"American Society of Hematology","year":"2012"},{"key":"10.1016\/j.thromres.2020.12.030_bb0170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MBC.0b013e32835274d9","article-title":"The condensed MCMDM-1 VWD bleeding questionnaire as a predictor of bleeding disorders in women with unexplained menorrhagia","volume":"23","author":"Azzam","year":"2012","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2020.12.030_bb0175","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease","volume":"123","author":"Federici","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.12.030_bb0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2516.2006.01393.x","article-title":"The 80th anniversary of von Willebrand\u2019s disease: history, management and research","volume":"12","author":"Federici","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0190","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/j.1538-7836.2006.02179.x","article-title":"The von Willebrand disease prophylaxis network: exploring a treatment concept","volume":"4","author":"Berntorp","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0195","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hae.13616","article-title":"Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: the THUNDER study","volume":"25","author":"Scott","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474086.2018.1564032","article-title":"Switching patients in the age of long-acting recombinant products?","volume":"12","author":"Escobar","year":"2019","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.thromres.2020.12.030_bb0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JBM.S103796","article-title":"Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?","volume":"8","author":"Lieuw","year":"2017","journal-title":"J. Blood Med."},{"key":"10.1016\/j.thromres.2020.12.030_bb0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/hae.13624","article-title":"Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP","volume":"25","author":"von Mackensen","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0215","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2020.12.030_bb0220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ejh.12809","article-title":"Von Willebrand disease - the \u2018Dos\u2019 and \u2018Don\u2019ts\u2019 in surgery","volume":"98","author":"Miesbach","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2020.12.030_bb0225","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40792-018-0528-y","article-title":"Administration of plasma-derived coagulation factor VIII during the perioperative period of mastectomy for breast cancer with acquired von Willebrand syndrome","volume":"4","author":"Sasaki","year":"2018","journal-title":"Surg. Case Rep."},{"key":"10.1016\/j.thromres.2020.12.030_bb0230","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"Suppl. 5","key":"10.1016\/j.thromres.2020.12.030_bb0235","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2516.2008.01851.x","article-title":"Prophylaxis in von Willebrand disease","volume":"14","author":"Berntorp","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0240","doi-asserted-by":"crossref","first-page":"100572","DOI":"10.1016\/j.blre.2019.04.001","article-title":"Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor","volume":"38","author":"Peyvandi","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2020.12.030_bb0245","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jth.14313","article-title":"Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery","volume":"17","author":"Peyvandi","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0250","first-page":"262","article-title":"Towards personalised therapy for von Willebrand disease: a future role for recombinant products","volume":"14","author":"Favaloro","year":"2016","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2020.12.030_bb0255","first-page":"391","article-title":"A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF\/FVIII concentrates in severe inherited von Willebrand disease","volume":"17","author":"Peyvandi","year":"2019","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2020.12.030_bb0260","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1055\/s-0036-1581106","article-title":"Prophylaxis in von Willebrand disease: coming of age?","volume":"42","author":"Saccullo","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0265","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/j.1365-2516.2012.02770.x","article-title":"Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey","volume":"18","author":"Zappa","year":"2012","journal-title":"Haemophilia"},{"issue":"Suppl. 6","key":"10.1016\/j.thromres.2020.12.030_bb0270","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0275","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2020.12.030_bb0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of von Willebrand\u2019s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0285","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2020.12.030_bb0290","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.12995","article-title":"Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network","volume":"13","author":"Abshire","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0295","author":"Humate-P\u00ae Prescribing Information"},{"key":"10.1016\/j.thromres.2020.12.030_bb0300","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2516.2006.01184.x","article-title":"Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding","volume":"12","author":"Coppola","year":"2006","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2020.12.030_bb0305","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0049-3848(09)70152-5","article-title":"Haemate P\/Humate-P: a systematic review","volume":"124","author":"Berntorp","year":"2009","journal-title":"Thromb. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2020.12.030_bb0310","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","article-title":"Long-term prophylaxis in von Willebrand disease","volume":"16","author":"Berntorp","year":"2005","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2020.12.030_bb0315","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1160\/TH10-09-0616","article-title":"Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study","volume":"105","author":"Halimeh","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0320","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0325","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MBC.0000000000000568","article-title":"Pharmacokinetics, efficacy, and safety of a plasma-derived VWF\/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)","volume":"28","author":"Lissitchkov","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2020.12.030_bb0330","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/JBM.S236789","article-title":"Pharmacokinetics, efficacy and safety of a plasma-derived VWF\/FVIII concentrate (formulation V) in pediatric patients with von Willebrand disease (SWIFTLY-VWD study)","volume":"11","author":"Auerswald","year":"2020","journal-title":"J. Blood Med."},{"key":"10.1016\/j.thromres.2020.12.030_bb0335","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients","volume":"5","author":"Borel-Derlon","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0340","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0037-1603362","article-title":"Successful use of a highly purified plasma von Willebrand factor concentrate containing little FVIII for the long-term prophylaxis of severe (type 3) von Willebrand\u2019s disease","volume":"43","author":"Simurda","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2020.12.030_bb0345","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/hae.13165","article-title":"Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease","volume":"23","author":"Mannucci","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2020.12.030_bb0350","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.seminhematol.2004.09.009","article-title":"von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis","volume":"42","author":"Martinelli","year":"2005","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.thromres.2020.12.030_bb0355","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.12.030_bb0360","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2020.12.030_bb0365","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0609.2011.01611.x","article-title":"When von Willebrand disease comes into age - a matter of change?","volume":"86","author":"Miesbach","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2020.12.030_bb0370","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/hae.13473","article-title":"Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network","volume":"24","author":"Holm","year":"2018","journal-title":"Haemophilia"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:44:41Z","timestamp":1758735881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":74,"alternative-id":["S0049384821000074"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.12.030","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translating the success of prophylaxis in haemophilia to von Willebrand disease","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}